Case Report

Primary human chorionic gonadotropin secreting germinoma of the corpus callosum

Foo Song Chuan Aaron, Chong Q. Q. Dawn, Chang T. E. Kenneth¹, Ng Wai Hoe², Soh Shui Yen³, Tham Chee Kian

Departments of Medical Oncology, National Cancer Centre, 11 Hospital Drive, Singapore 169610, ¹Laboratory Medicine, ³Children’s Cancer Centre, KK Women and Children’s Hospital, 100 Bukit Timah Road, Singapore 229899, ²Neurosurgery, National Neuroscience Institute, Duke-NUS Graduate Medical School, 11 Jalan Tan Tock Seng, Singapore 308433

E-mail: *Foo Song Chuan Aaron - aaronfoosongchuan@hotmail.com; Chong Q. Q. Dawn - dawn.chong.q.q@nccs.com.sg; Chang T. E. Kenneth - kenneth.chang.t.e@kkh.com.sg; Ng Wai Hoe - wai_hoe_ng@nni.com.sg; Soh Shui Yen - Soh.Shui.Yen@kkh.com.sg; Tham Chee Kian - tham.c.k@nccs.com.sg

*Corresponding author

Received: 20 August 13   Accepted: 23 August 13  Published: 08 October 13

This article may be cited as:
Aaron FC, Dawn CQ, Kenneth CT, Hoe NW, Yen SS, Kian TC. Primary human chorionic gonadotropin secreting germinoma of the corpus callosum. Surg Neurol Int 2013;4:137.
Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2013/4/1/137/119537

Copyright: © 2013 Aaron FSC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Primary intracranial germinomas are a rare subset of intracranial tumors derived from mis-incorporated germ cells within the folding neural plate during embryogenesis. Though known to arise from midline structures in the central nervous system (CNS), occurrence within the corpus callosum is exceedingly rare.

Case Description: We present a rare case of secreting primary intracranial germinoma with extensive intraventricular metastasis presenting as a multi-cystic butterfly lesion in the genu of the corpus callosum in a young boy.

Conclusion: Intracranial germ cell tumors must be considered for any multi-cystic lesion arising from midline structures in the CNS in the preadult population.

Key Words: Corpus callosum, germinoma, intracranial, secreting

INTRODUCTION

Primary intracranial germinomas are an extremely rare subset of germ cell tumors (GCT) that arise primarily from midline structures in the central nervous system (CNS). Intracranial germinomas account for 0.5-2.0% of all intracranial tumors and 50-60% of CNS GCT. The two locations where these tumors are most commonly found are the pineal region and the suprasellar region. Other less common regions where these tumors have been found include the basal ganglia, the thalami, the corona radiate, temporal lobe, cerebellopontine angle, medulla oblongata, and intramedullary spinal cord. A proposed explanation for the location of these tumors in midline structures of the CNS is the mis-incorporation of primordial germ cells into the cranially migrating intraembryonic mesoderm during the formation of the primitive streak in the third week of embryogenesis. These germ cells commonly arise from structures lying laterally adjacent to the embryonic disc, such as the trophoblastic layer, amnion, and yolk sac endoderm. During the subsequent folding of the neural plate into the neural tube, these cells are mistakenly enfolded and incorporated into the CNS, where they may give rise to GCT in future.

We present a rare case of primary intracranial GCT arising from the corpus callosum in a 15-year-old child treated at our institution.
CASE REPORT

History
A 15-year-old Malay boy with no significant past medical history was referred to our institution with a 2-month history of intermittent fever, recurrent headaches, vomiting, significant weight loss, and deterioration in school performance. He did not have any significant drug, family, or developmental history.

Physical examination
On examination, he was found to be disorientated to time, place, and person. He also demonstrated terminal past-pointing bilaterally and left-sided dysdiadochokinesia.

Investigations
Initial blood investigations revealed a white blood cell count of 6.92×10^9/L and a C-reactive protein level of <5.0 mg/L. Serum alphafetoprotein (AFP) and human chorionic gonadotropin (b-HCG) were not elevated. Other abnormal serum biochemical parameters included free thyroxine (FT4) of 9.4 pmol/L, thyroid stimulating hormone (TSH) of 3.92 mIU/L, follicular stimulating hormone of <0.1 IU/L, luteinizing hormone of <0.07 IU/L, sodium of 155 mmol/L and serum osmolality of 323 mOsm/kg. Cerebrospinal fluid (CSF) AFP levels were normal but CSF b-HCG levels, however, were markedly elevated at 1837.01 IU/L. Contrasted computer tomographic (CT) imaging revealed a heterogenous 4 cm mass centered in the genu of the corpus callosum, filling the anterior aspect of the third ventricle and spreading along the margins of both frontal horns, the genu of the corpus callosum and the septum pellucidum, inferiorly into the suprasellar region, as well as laterally into the right temporal horn [Figure 1]. Small cystic foci were also noted in the vicinity of the pineal gland. MRI attempted at this juncture was not augmented with contrasted medium due to acute kidney injury from excessive diuresis precipitated by central diabetes insipidus. No spinal drop metastases were visualized on MRI.

Pathological findings
The patient underwent open craniotomy and biopsy of the intraventricular portion of the tumor. Histology revealed a germinoma composed of sheets of large primitive cells with round nuclei bearing prominent nucleoli, and ample clear cytoplasm with discrete cell membranes, interrupted by fibrous septa containing smaller reactive lymphocytes [Figure 3]. Immunohistochemical staining showed positive reactivity for CD117 (c-kit) and placental alkaline phosphatase, confirming the diagnosis of germinoma. Although CSF b-HCG was found to be elevated at 1837.01 IU/L, immunohistochemical staining for the same was negative.

Postoperative course
The patient underwent four cycles of carboplatin, etoposide, and ifosfamide as per International Society of Pediatric Oncology Central Nervous System Germ Cell Tumor (SIOP CNS GCT) 96 protocol and subsequent craniospinal irradiation (CSI) of 54 Gray (Gy) in 32 fractions, which he tolerated well. Radiologically, his lesions remained stable despite completing treatment [Figure 4] but he demonstrated good biochemical response with CSF b-HCG falling from
1837.01 IU/L to less than 2.0 IU/L. The patient had to be on permanent hormonal replacement therapy for panhypopituitarism. His last CSF b-HCG reading taken 12 months after completion of treatment remains stable at <1.2 IU/L and most recent MRI brain done 15 months after completion of treatment shows no evidence of recurrence.

**DISCUSSION**

Lesions of the corpus callosum are often mentioned in association with aggressively infiltrative tumors such as glioblastoma multiforme (GBM) or demyelinating diseases such as multiple sclerosis.[2] The occurrence of primary CNS GCT in the corpus callosum is extremely rare and oftentimes not considered among other preoperative differential diagnoses. GCT are largely a disease of the preadult age group, with majority of afflicted patients no older than the age of 20.[5,15,26] On CT imaging, a proportion (19%) of these tumors may show calcification.[13] On MRI, these tumors may demonstrate the following: Hypointensity to isointensity on T1-weighted MRI, hyperintensity to isointensity on T2-weighted MRI, homogenous enhancement with gadolinium contrast on MRI, and a multi-cystic appearance.[5,13] The presence of a multi-cystic tumor in a midline location in an adolescent should therefore always raise the suspicion of a GCT; the significance being that these tumors have a relatively better prognosis than most other malignant brain tumors and are readily treatable with chemotherapy and radiation, hence averting morbid surgery.

As the genu of the corpus callosum constitutes the roof of the frontal horns, tumor spread along the CSF pathways probably accounts for the extent of intraventricular dissemination seen in this patient. Tumors of the corpus callosum are known to have progressed extensively before the manifestation of symptoms due to their location’s relatively noneloquent nature.[23]

Raised CSF b-HCG levels coupled with histological confirmation of germinoma suggest the following differential diagnoses: (1) germinoma with syncytiotrophoblastic giant cells (STGC), (2) HCG-secreting germinoma, or (3) mixed GCT with both germinomatous and nongerminomatous components. The latter is especially in the light of a markedly raised tumor markers (b-HCG) as described in our case report.[5,29] Tumor marker levels in non-germinomatous germ cell tumors (NGGCT) tend to be higher, but to date, there is no definitive cut-off value that distinguishes germinoma from NGGCT, although it is commonly quoted that germinomas secrete b-HCG only up to levels of 50.0 IU/L. Cases of germinomas secreting very high levels of b-HCG have been documented,[5,21] complicating distinction between the former and NGGCT. No STGC were identified in our patient’s specimen even after detailed histological examination and B-HCG immunohistochemical staining performed was negative. It is possible that any STGC or nongerminomatous component could have been missed on biopsy of the tumor. Any difference in prognosis between HCG-secreting germinoma and germinoma with STGC remains unclear to date.[10,21] Nevertheless, secreting germinomas and NGGCT tend to be less responsive than nonsecreting or ‘pure’ germinomas to treatment, hence portending a poorer prognosis.[6] HCG-secreting germinomas have demonstrated significantly worse outcomes vis-a-vis their nonsecreting counterparts when treated with both chemotherapy and radiation[1] as well as with radiation-alone.[6]

Treatment outcomes comparable with that of unifocal germinomas has been shown to be possible for initially disseminated intracranial germinomas (IDIG). A small single-institution series showed excellent outcomes

**Figure 3:** Photomicrograph of germinoma (H and E, ×200) featuring sheets of large primitive cells with round nuclei bearing prominent nucleoli, and ample clear cytoplasm with discrete cell membranes, interrupted by fibrous septa containing smaller reactive lymphocytes

**Figure 4:** Contrasted MRI 1 month after completion of treatment

http://www.surgicalneurologyint.com/content/4/1/137
for IDIG treated with intensive platinum-based chemotherapy combined with CSI (median dose 30.0 Gy; range 21.0-36.0 Gy) and focal boosts to both primary and secondary lesions (median dose 30.6 Gy; range 30.6-55.0 Gy) with minimal long-term side effects.[5] This study highlighted the possibility of achieving disease outcomes similar to unifocal lesions in the IDIG group with appropriate treatment. The SIOP CNS GCT 96 trial, in contrast, revealed that treatment with CSI (24.0 Gy) with tumor bed boost (additional 16.0 Gy) alone in the IDIG group achieved excellent outcomes with 5 year overall survival (OS) and event-free survival (EFS) of 98% and that the addition of platinum-based chemotherapy to radiation conferred no additional survival benefit.[5] These findings suggest that radiation should be the key treatment modality in IDIG but definitive consensus on the optimum treatment for this group requires further confirmation with more clinical trials.

Remnant lesions are risk factors for recurrence in most pediatric cancers but appear not to be in the case of germinoma. The appearance of a residual lesion after completion of treatment with chemotherapy suggests the possibility of remnant fibrosis/necrosis or a residual nongerminomatous component that was missed on histological sampling in the first place, the most significant of which is a mature teratomatous component. A distinct phenomenon known as the ‘growing teratoma syndrome’ in which the tumor mass is seen to enlarge during or after chemotherapy in the presence of falling serum markers has been reported.[16] This is not to be confused with disease recurrence as the treatment for teratoma is surgical excision while that of recurrent germinoma is further chemotherapy and/or irradiation. There has been renewed interest in the role of relook surgery to assess residual lesions, especially in the setting of normalization of serum/CSF tumor markers given the likelihood of a residual teratomatous component.[5]

**CONCLUSION**

Intracranial GCT must be considered for a multi-cystic lesion arising from midline structures in the CNS in the preadult population. Histological sampling must be interpreted in the context of serum/CSF biochemical markers to achieve accurate diagnosis. Treatment outcomes of IDIG are excellent if appropriate therapy can be administered.

**REFERENCES**

1. Aoyama H, Shirato H, Ikeda J, Fujieda K, Miyazaki K, Sawamura Y. Induction chemotherapy followed by low-dose involved-field radiotherapy for intracranial germ cell tumors. J Clin Oncol 2002;20:857-65.
2. Bourreiras EC, Varakis K, Bruns D, Christoforidis GA, Baujan M, Slone HW, et al. Lesions of the corpus callosum: MR imaging and differential considerations in adults and children. AJR Am J Roentgenol 2002;179:251-7.
3. Calaminus G, Kortmann R, Woroch J, Nicholson JC, Alapetite C, Garrè ML, et al. SIOP CNS GCT 96: Final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease. Neuro Oncol 2013;15:788-96.
4. Carrillo R, Ricoy JR, Del Pozo JM, García-Uria J, Herrero J. Dissemination with malignant changes from a pineal tumor through the corpus callosum after total removal. Childs Brain 1977;4:320-7.
5. Chen YW, Huang PI, Hu YW, Ho DM, Chang KP, Guo WY, et al. Treatment strategies for initially disseminated intracranial germinomas: Experiences at a single institute. Childs Nerv Syst 2012;28:557-63.
6. Echevarría ME, Fanguardo J, Goldman S. Pediatric central nervous system germ cell tumors: A review. Oncologist 2008;13:690-9.
7. Fujimaki T, Matsutani M. HCG-producing germinoma: Analysis of Japanese Pediatric Brain Tumour Study Group results. Neuro Oncol 2005;7:513-33.
8. Fujiwara K, Ueno Hara H, Suzuki H, Sakurai Y. Intracranial germinoma with syncytiotrophoblastic giant cells in the cerebellopontine angle: Case report. Neurourol Med Chir (Tokyo) 2002;42:132-6.
9. Horwowitz MB, Hall WA. Central nervous system germinomas: A review. Arch Neurol 1991;48:652-7.
10. Inamura T, Nishio S, Ikekazi K, Fukui M. Human chorionic gonadotrophin in CSF, not serum, predicts outcome in germinoma. J Neurol Neurosurg Psychiatry 1999;66:654-7.
11. Kamoshina Y, Sawamura Y, Iwasaki M, Iwasaki Y, Sugiyama K. Metachronous mature teratoma in the corpus callosum occurring 12 years after a pineal germinoma. J Neurosurg 2008;109:126-9.
12. Kawai N, Miyake K, Nishiyama Y, Miki A, Haba R, et al. Targeting optimal biopsy location in basal ganglia germinoma using (11) C-methionine positron emission tomography. Surg Neurol 2008;70:408-13.
13. Liang L, Korogi Y, Sugahara T, Ikushima I, Shigematsu Y, Okuda T, et al. MRI of intracranial germ-cell tumours. Neuroradiology 2002;44:382-8.
14. Madhukar M, Maller VG, Choudhary AK, Iantosca MR, Specht CS, Dias MS, et al. Targeting optimal biopsy location in basal ganglia germinoma using (11) C-methionine positron emission tomography. Surg Neurol 2008;70:408-13.
15. McCarthy BJ, Shibui S, Kayama T, Miyaoka Y, Murakami M, et al. Primary CNS germ cell tumors in Japan and the United States: An analysis of 4 tumor registries. Neuro Oncol 2012;14:1194-200.
16. O’Callaghan AM, Katapodis O, Ellison DW, Theaker JM, Mead GM. The growing teratoma syndrome in a nongerminomatous germ cell tumor of the pineal gland: A case report and review. Cancer 1997;80:942-7.
17. Packer RJ, Cohen BH, Coney K. Intracranial germ cell tumors. Oncologist 2005;5:312-20.
18. Sano K. Pathogenesis of intracranial germ cell tumors reconsidered. J Neurosurg 1999;90:258-64.
19. Sano K, Matsutani M, Seto T. So-called intracranial germ cell tumours: Personal experiences and a theory of their pathogenesis. Neurol Res 1989;11:118-26.
20. Sartori S, Laverda AM, Calderone M, Carollo C, Viscardi E, Faggian R, et al. Germinoma with synchronous involvement of midline and off-midline structures associated with progressive hemiparesis and hemiatrophy in a young adult. Childs Nerv Syst 2007;23:1341-5.
21. Shibamoto Y, Takahashi M, Sasi K. Prognosis of intracranial germinoma with syncytiotrophoblastic giant cells treated by radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:505-10.
22. So SC, Ho J. Multiple primary germinomas (ectopic pinealoma) of the brain. Neurochirurgie (Stuttgart) 1980;23:147-50.
23. Sugiyama S, Kurnabe T, Mino M, Fujimura M, Fujikawa I, Tominaga T. Precocious puberty caused by hCG-producing germinoma involving the bilateral basal ganglia and cerebral white matter without typical radiologic findings: Case report. No Shinkei Geka 2006;34:619-24.
24. Tamaki N, Lin T, Shirakaki K, Hosoda K, Kurata H, Matsumoto S, et al. Germ cell tumors of the thalamus and the basal ganglia. Childs Nerv Syst 1990;6:3-7.
25. Utsuki S, Oka H, Tanizaki Y, Kondo K, Fuji K. Radiological features of germinoma arising from atypical locations. Neurol Med Chir (Tokyo) 2005;45:268-71.
26. Villano JL, Propp JM, Porter KR, Stewart AK, Vally-Nagy T, Li X, et al. Malignant pineal germ-cell tumors: An analysis of cases from three tumor registries. Neuro Oncol 2008;10:121-30.
27. Voirin J, Klein O, Chastagner P, Moret C, Vignaud JM, Auque J, et al. Germ-cell tumors of the central nervous system in childhood: Retrospective study of 13 patients. Neurochirurgie 2008;54:55-62.
28. Yen FS, Chou AS, Chen CJ, Jung SM, Chuang HL, Scott RM. Primary medulla oblongata germinoma: A case report and review of the literature. J Neurooncol 2003;62:339-42.
29. Yonezawa H, Shinsato Y, Obara S, Oyoshi T, Hirano H, Kitajima S, et al. Germinoma with syncytiotrophoblastic giant cells arising in the corpus callosum. Neurol Med Chir (Tokyo) 2010;50:588-91.

Disclaimer: The authors of this article have no conflicts of interest to disclose, and have adhered to SNI's policies regarding human/animal rights, and informed consent. Advertisers in SNI did not ask for, nor did they receive access to this article prior to publication.